Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2015
Summary
Global Markets Directs, Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2015, provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD)s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Non Alcoholic Fatty Liver Disease (NAFLD)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Non Alcoholic Fatty Liver Disease (NAFLD) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Non Alcoholic Fatty Liver Disease (NAFLD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Non Alcoholic Fatty Liver Disease (NAFLD) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Non Alcoholic Fatty Liver Disease (NAFLD) Overview 9
Therapeutics Development 10
Pipeline Products for Non Alcoholic Fatty Liver Disease (NAFLD) - Overview 10
Pipeline Products for Non Alcoholic Fatty Liver Disease (NAFLD) - Comparative Analysis 11
Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics under Development by Companies 12
Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics under Investigation by Universities/Institutes 14
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Non Alcoholic Fatty Liver Disease (NAFLD) - Products under Development by Companies 18
Non Alcoholic Fatty Liver Disease (NAFLD) - Products under Investigation by Universities/Institutes 20
Non Alcoholic Fatty Liver Disease (NAFLD) - Companies Involved in Therapeutics Development 21
Arisaph Pharmaceuticals, Inc. 21
Conatus Pharmaceuticals Inc. 22
Daewoong Pharmaceutical Co., Ltd. 23
Dimerix Bioscience Pty Ltd 24
Dr. Falk Pharma GmbH 25
DURECT Corporation 26
Galmed International Ltd. 27
Gilead Sciences, Inc. 28
Huons Co., Ltd. 29
Kyorin Pharmaceutical Co., Ltd. 30
Metabolic Solutions Development Company, LLC 31
Novartis AG 32
Raptor Pharmaceuticals Corp. 33
TCM Biotech International Corp 34
Tobira Therapeutics, Inc. 35
Verva Pharmaceuticals Limited 36
Zafgen Inc. 37
Zydus Cadila Healthcare Limited 38
Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Target 40
Assessment by Mechanism of Action 42
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 47
Aramchol - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
ARI-3037MO - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
C-10 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
cenicriviroc mesylate - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
cysteamine DR - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
DMX-300 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Drugs to Inhibit ABHD6 for Gastrointestinal and Metabolic Disorders - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
DUR-928 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
DWP-10292 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
emricasan - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
HU-002 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
KDT-501 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
MAT-8800 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
MB-12066 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
methazolamide - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
MN-002 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
MSDC-0602 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
norursodeoxycholic acid - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
oltipraz - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
pradigastat sodium - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Px-102 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Px-103 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Px-104 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
saroglitazar - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Small Molecules to Activate AMPK for Fatty Liver Disease - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Small Molecules to Inhibit NaCT for Metabolic Diseases - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
TCM-606F - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
VVP-100-X - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
ZGN-839 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Non Alcoholic Fatty Liver Disease (NAFLD) - Recent Pipeline Updates 85
Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Projects 103
Non Alcoholic Fatty Liver Disease (NAFLD) - Product Development Milestones 104
Featured News & Press Releases 104
May 18, 2015: DURECT Announces Positive Results from DUR-928 Multi-Dose Phase 1 Study 104
Apr 23, 2015: Conatus Clinical Results at EASL Meeting Support Emricasan Registration Pathway in NASH 104
Apr 08, 2015: Conatus Pharmaceuticals to Present Three Emricasan Clinical Results Posters at EASL Meeting 106
Mar 30, 2015: DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 107
Mar 26, 2015: Conatus Announces Successful Top-Line Results From NAFLD/NASH Clinical Trial of Emricasan 107
Mar 02, 2015: DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 108
Apr 28, 2014: Galmed Pharmaceuticals Commences Patient Screening for Aramchol Pharmacokinetic and Food Effect Studies 109
Oct 31, 2012: Phenex Pharma Completes Phase I Studies With FXR-Agonist Px-102 110
Appendix 111
Methodology 111
Coverage 111
Secondary Research 111
Primary Research 111
Expert Panel Validation 111
Contact Us 111
Disclaimer 112
List Of Tables
Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H2 2015 10
Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD) - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 13
Number of Products under Investigation by Universities/Institutes, H2 2015 14
Comparative Analysis by Late Stage Development, H2 2015 15
Comparative Analysis by Clinical Stage Development, H2 2015 16
Comparative Analysis by Early Stage Development, H2 2015 17
Products under Development by Companies, H2 2015 18
Products under Development by Companies, H2 2015 (Contd..1) 19
Products under Investigation by Universities/Institutes, H2 2015 20
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2015 21
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Conatus Pharmaceuticals Inc., H2 2015 22
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2015 23
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Dimerix Bioscience Pty Ltd, H2 2015 24
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Dr. Falk Pharma GmbH, H2 2015 25
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by DURECT Corporation, H2 2015 26
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Galmed International Ltd., H2 2015 27
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Gilead Sciences, Inc., H2 2015 28
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Huons Co., Ltd., H2 2015 29
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2015 30
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Metabolic Solutions Development Company, LLC, H2 2015 31
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Novartis AG, H2 2015 32
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Raptor Pharmaceuticals Corp., H2 2015 33
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by TCM Biotech International Corp, H2 2015 34
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Tobira Therapeutics, Inc., H2 2015 35
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Verva Pharmaceuticals Limited, H2 2015 36
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Zafgen Inc., H2 2015 37
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Zydus Cadila Healthcare Limited, H2 2015 38
Assessment by Monotherapy Products, H2 2015 39
Number of Products by Stage and Target, H2 2015 41
Number of Products by Stage and Mechanism of Action, H2 2015 43
Number of Products by Stage and Route of Administration, H2 2015 45
Number of Products by Stage and Molecule Type, H2 2015 46
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics - Recent Pipeline Updates, H2 2015 85
Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Projects, H2 2015 103
List Of Figures
List of Figures
Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H2 2015 10
Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD) - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 12
Comparative Analysis by Clinical Stage Development, H2 2015 16
Comparative Analysis by Early Stage Products, H2 2015 17
Assessment by Monotherapy Products, H2 2015 39
Number of Products by Top 10 Targets, H2 2015 40
Number of Products by Stage and Top 10 Targets, H2 2015 40
Number of Products by Top 10 Mechanism of Actions, H2 2015 42
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 42
Number of Products by Top 10 Routes of Administration, H2 2015 44
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 44
Number of Products by Stage and Top 10 Molecule Types, H2 2015 46
